Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2015-12-04FDA Approved: SYNJARDY — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for SYNJARDY (empagliflozin and metformin hydrochloride) from Boehringer Ingelheim Pharmaceuticals, …
-
FDA approval · 2015-11-25FDA Approved: HUMALOG KWIKPEN — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for HUMALOG KWIKPEN (insulin lispro) submitted by Eli Lilly, resulting in a labeling action for the …
-
FDA approval · 2015-11-05FDA Approved: PIOGLITAZONE AND METFORMIN HYDROCHLORIDE — Original Application (Macleods Pharmaceuticals Limited)
FDA approves Macleods Pharmaceuticals Limited's Pioglitazone and Metformin Hydrochloride as an original ANDA. The product is indicated for t…
-
FDA approval · 2015-10-27FDA Approved: GLIMEPIRIDE — Supplemental Application (Solco Healthcare U.S., LLC)
FDA approved a supplemental application for glimepiride from Solco Healthcare U.S., LLC (generic) to market the product.
-
FDA approval · 2015-10-20FDA Approved: HUMULIN N — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for HUMULIN N (insulin human) from Eli Lilly and Company.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2015-10-05FDA Approved: GLUCOTROL XL — Supplemental Application (Roerig)
FDA approved a supplemental application for GLUCOTROL XL (glipizide) from Roerig, resulting in changes to the product labeling.
-
FDA approval · 2015-09-29FDA Approved: TOUJEO — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for TOUJEO (insulin glargine) from Sanofi-Aventis U.S. LLC.
-
FDA approval · 2015-09-28FDA Approved: METFORMIN HYDROCHLORIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for Metformin hydrochloride from Sun Pharmaceutical Industries, marking an updated approval for …
-
FDA approval · 2015-09-25FDA Approved: TRESIBA — Original Application (Novo Nordisk)
FDA approved the original Biologics License Application for Tresiba (insulin degludec) from Novo Nordisk, establishing a long-acting insulin…
-
FDA approval · 2015-09-18FDA Approved: JENTADUETO — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approved a supplemental application for JENTADUETO (linagliptin/metformin hydrochloride) from Boehringer Ingelheim Pharmaceuticals, …
-
FDA approval · 2015-09-18FDA Approved: PIOGLITAZONE HCL AND METFORMIN HCL — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved Torrent Pharmaceuticals Limited's supplemental application for a generic Pioglitazone HCl and Metformin HCl combination product…
-
FDA approval · 2015-09-16FDA Approved: AFREZZA — Supplemental Application (Mannkind Corporation)
The FDA approved a supplemental application for AFREZZA (insulin human) from MannKind Corporation.
-
FDA approval · 2015-09-10FDA Approved: INSULIN LISPRO — Supplemental Application (Eli Lilly and Company)
The FDA has granted a supplemental approval for insulin lispro submitted by Eli Lilly and Company.
-
FDA approval · 2015-09-09FDA Approved: INVOKANA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Invokana (canagliflozin) from Janssen Pharmaceuticals, Inc.
-
FDA approval · 2015-09-03FDA Approved: GLYBURIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for GLYBURIDE submitted by Teva Pharmaceuticals USA, Inc.
-
FDA approval · 2015-09-02FDA Approved: GLYBURIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for GLYBURIDE submitted by Teva Pharmaceuticals USA, Inc. Glyburide is used to treat type 2 diabetes…
-
FDA approval · 2015-09-01FDA Approved: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for a fixed-dose combination of dapagliflozin and metformin hydrochloride, manufactured by Prasco La…
-
FDA approval · 2015-08-28FDA Approved: JANUVIA — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for Januvia (sitagliptin) from Merck Sharp & Dohme LLC.
-
FDA approval · 2015-08-28FDA Approved: JENTADUETO — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approved a supplemental application for JENTADUETO (linagliptin and metformin hydrochloride) submitted by Boehringer Ingelheim Pharm…
-
FDA approval · 2015-08-28FDA Approved: JANUMET XR — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for JANUMET XR, adding an extended-release formulation of sitagliptin and metformin hydrochloride. T…
-
FDA approval · 2015-08-28FDA Approved: ALOGLIPTIN — Supplemental Application (Padagis Israel Pharmaceuticals Ltd)
FDA approved a supplemental application for alogliptin submitted by Padagis Israel Pharmaceuticals Ltd.
-
FDA approval · 2015-08-28FDA Approved: KAZANO — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for KAZANO (alogliptin and metformin hydrochloride) by Takeda Pharmaceuticals America, Inc.
-
FDA approval · 2015-08-28FDA Approved: TRADJENTA — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for Tradjenta (linagliptin) from Boehringer Ingelheim Pharmaceuticals, Inc. This action approves a s…
-
FDA approval · 2015-08-28FDA Approved: ALOGLIPTIN AND PIOGLITAZONE — Supplemental Application (Padagis Israel Pharmaceuticals Ltd)
FDA approved a supplemental application for a fixed-dose combination of alogliptin benzoate and pioglitazone hydrochloride to treat type 2 d…
-
FDA approval · 2015-08-28FDA Approved: GLYXAMBI — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approved a supplemental application for GLYXAMBI (empagliflozin and linagliptin) submitted by Boehringer Ingelheim Pharmaceuticals, …